Evidence map›Paper›PMID 42494593›Full record

ArticleFrontiers in oncology2026

Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines.

Valentina G Ferreira, Maria Eduarda Ehlert, Bruna S Pacheco, Fernanda S S Souza, Isadora Tisoco, Lucas Damé Simões, Bernardo A Iglesias, Claudia Ó Pessoa, Fabiana K Seixas, Maria Lucia Z Dagli and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Valentina G Ferreira *Molecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.
Maria Eduarda Ehlert *Molecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.
Bruna S PachecoMolecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.
Fernanda S S SouzaMolecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.
Isadora TisocoDepartment of Chemistry, Federal University of Santa Maria, Santa Maria, Brazil.
Lucas Damé SimõesMolecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.
Bernardo A IglesiasDepartment of Chemistry, Federal University of Santa Catarina, Florianópolis, Brazil.
Claudia Ó PessoaINCT T-Bio2: Translational Biodiscovery and Biomodels, Pelotas, Rio Grande do Sul, Brazil.
Fabiana K SeixasMolecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.
Maria Lucia Z DagliINCT T-Bio2: Translational Biodiscovery and Biomodels, Pelotas, Rio Grande do Sul, Brazil.
Laurie A RundDepartment of Animal Sciences, University of Illinois, Urbana, IL, United States.
Kyle M SchachtschneiderINCT T-Bio2: Translational Biodiscovery and Biomodels, Pelotas, Rio Grande do Sul, Brazil.
Lawrence B SchookINCT T-Bio2: Translational Biodiscovery and Biomodels, Pelotas, Rio Grande do Sul, Brazil.
Tiago Veiras CollaresMolecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bladder cancer remains a highly recurrent malignancy with limited long-term response to conventional therapies. The development of new treatments is also hindered by the lack of preclinical models that accurately reproduce human disease. In this context, Oncopig-derived models provide a translationally relevant platform for evaluating candidate therapies before progression to Methods: Here, we performed a preclinical Results: All three compounds exhibited light-dependent cytotoxicity with minimal dark toxicity. While 3-Pd(PPh Conclusion: These findings support the translational potential of Pd(II)-porphyrins for bladder cancer PDT and position Oncopig-derived

Indexed as

bladder cancerOncopig cancer modelpalladium(II)-porphyrinsphotodynamic therapypreclinical screeningtranslational oncology

Identifiers

PMID42494593
PMCPMC13391413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.